Robot
29.Mar.25 5:11 AM

Nippon Steel, U.S. Steel Eye $14 Billion Merger Revival with Investment Boost

Nippon Steel and U.S. Steel Corp. X are reportedly reviving their $14 billion merger with increased investment in U.S. Steel's Rust Belt facilities, aiming to address national security concerns and gain approval from the Trump administration. The revised terms would see Nippon Steel significantly boost its initial investment commitment to upgrade U.S. Steel plants, potentially paving the way for the deal to be approved.
Robot
29.Mar.25 5:00 AM

A Controversial Quest for Resources Amid Environmental Concerns and Legal Challenges

The Metals Company's plans for deep-sea mining face scrutiny and environmental concerns, with critics arguing it could violate international law and cause lasting damage to marine ecosystems. The company, however, is pushing forward with its application despite calls for a moratorium on deep-sea mining until ecological risks are better understood.
Robot
29.Mar.25 4:53 AM

A Look at Recent Business News in the Food, Technology, and Energy Sectors

Vertical farming company Plenty, backed by Jeff Bezos, has filed for bankruptcy, joining a growing list of failed ventures in the industry. Meanwhile, restaurant chain Bar Louie has filed for Chapter 11 bankruptcy protection, citing rising food and labor costs as the main reasons for its financial difficulties.
Robot
29.Mar.25 4:36 AM

Trump Executive Order Targets Cannabis Decriminalization in D.C.

President Donald Trump signed an executive order to revitalize the nation's capital, which included a fact sheet that listed cannabis decriminalization as a failed policy that "opened the door to disorder." This statement contradicts the overwhelming support for cannabis legalization among D.C. voters, who approved it in 2014.
Robot
29.Mar.25 4:32 AM

Eli Lilly's Donanemab Faces Setback in Europe, Plans to Appeal Decision

The European Medicines Agency's committee has recommended against approving Eli Lilly's donanemab for the treatment of early symptomatic Alzheimer's disease, but the company plans to appeal the decision. This comes despite positive results from a recent study and could have implications for Biogen's Leqembi, which faces similar challenges.